{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T21:46:56Z","timestamp":1791841616853,"version":"4.3.4"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Obesity Pillars"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.obpill.2026.100333","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T09:19:20Z","timestamp":1789723160000},"page":"100333","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Evaluation of clinical relevance of weight nadirs and weight regain during 3 years of treatment with tirzepatide in participants with obesity or overweight and prediabetes"],"prefix":"10.1016","volume":"20","author":[{"given":"Louis J.","family":"Aronne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0743-4189","authenticated-orcid":false,"given":"Royce P.","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5894-9054","authenticated-orcid":false,"given":"Klara R.","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia Fraseur","family":"Brumm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3180-3638","authenticated-orcid":false,"given":"Irina","family":"Jouravskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dachuang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6662-804X","authenticated-orcid":false,"given":"Georgios K.","family":"Dimitriadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9561-0183","authenticated-orcid":false,"given":"Julia P.","family":"Dunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.obpill.2026.100333_bib1","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1001\/jama.2023.24945","article-title":"Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial","volume":"331","author":"Aronne","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.obpill.2026.100333_bib2","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1111\/dom.14725","article-title":"Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension","volume":"24","author":"Wilding","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.obpill.2026.100333_bib3","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.obpill.2026.100333_bib4","article-title":"Cardiometabolic parameter change by weight regain on tirzepatide withdrawal in adults with obesity: a post hoc analysis of the SURMOUNT-4 trial","author":"Horn","year":"2025","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.obpill.2026.100333_bib5","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1136\/heartjnl-2021-320171","article-title":"Antihypertensive drug effects on long-term blood pressure: an individual-level data meta-analysis of randomised clinical trials","volume":"108","author":"Canoy","year":"2022","journal-title":"Heart"},{"key":"10.1016\/j.obpill.2026.100333_bib6","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2337\/dc24-2419","article-title":"Differential treatment effects on \u03b2-Cell function using model-based parameters in type 2 diabetes: results from the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE)","volume":"48","author":"Utzschneider","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.obpill.2026.100333_bib7","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3389\/fimmu.2020.00589","article-title":"What is the clinical relevance of TNF inhibitor immunogenicity in the management of patients with rheumatoid arthritis?","volume":"11","author":"Mehta","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.obpill.2026.100333_bib8","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa066224","article-title":"Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy","volume":"355","author":"Kahn","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.obpill.2026.100333_bib9","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1517\/14728222.12.4.425","article-title":"Potential therapeutic targets for Parkinson's disease","volume":"12","author":"Stoessl","year":"2008","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.obpill.2026.100333_bib10","first-page":"183","article-title":"Maintenance of lost weight and long-term management of obesity","volume":"102","author":"Hall","year":"2018","journal-title":"Med Clin"},{"key":"10.1016\/j.obpill.2026.100333_bib11","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa2410819","article-title":"Tirzepatide for obesity treatment and diabetes prevention","volume":"392","author":"Jastreboff","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.obpill.2026.100333_bib12","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1038\/s41366-023-01388-0","article-title":"Waist to height ratio as a simple tool for predicting mortality: a systematic review and meta-analysis","volume":"47","author":"Dezfouli","year":"2023","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.obpill.2026.100333_bib13","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.2337\/dc25-0763","article-title":"Tirzepatide treatment and associated changes in \u03b2-Cell function and insulin sensitivity in people with obesity or overweight with prediabetes or normoglycemia: a post hoc analysis from the SURMOUNT-1 trial","volume":"48","author":"Mari","year":"2025","journal-title":"Diabetes Care"},{"key":"10.1016\/j.obpill.2026.100333_bib14","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1017\/S0007114519003301","article-title":"A simple cut-off for waist-to-height ratio (0\u00b75) can act as an indicator for cardiometabolic risk: recent data from adults in the Health Survey for England","volume":"123","author":"Gibson","year":"2020","journal-title":"Br J Nutr"},{"key":"10.1016\/j.obpill.2026.100333_bib15","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1001\/jama.2018.14433","article-title":"Comparison of the performance of common measures of weight regain after bariatric surgery for association with clinical outcomes","volume":"320","author":"King","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.obpill.2026.100333_bib16","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1002\/oby.70011","article-title":"Tirzepatide associated with improved health-related quality of life in adults with obesity or overweight in SURMOUNT-4","volume":"33","author":"Gibble","year":"2025","journal-title":"Obesity"},{"key":"10.1016\/j.obpill.2026.100333_bib17","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1056\/NEJMoa066254","article-title":"Effects of bariatric surgery on mortality in Swedish Obese Subjects","volume":"357","author":"Sj\u00f6str\u00f6m","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.obpill.2026.100333_bib18","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa2002449","article-title":"Life expectancy after bariatric surgery in the Swedish Obese Subjects study","volume":"383","author":"Carlsson","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.obpill.2026.100333_bib19","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1136\/heartjnl-2024-324170","article-title":"Tirzepatide and blood pressure reduction: stratified analyses of the SURMOUNT-1 randomised controlled trial","volume":"110","author":"Krumholz","year":"2024","journal-title":"Heart"}],"container-title":["Obesity Pillars"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667368126000896?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667368126000896?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T21:08:32Z","timestamp":1791839312000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667368126000896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":19,"alternative-id":["S2667368126000896"],"URL":"https:\/\/doi.org\/10.1016\/j.obpill.2026.100333","relation":{},"ISSN":["2667-3681"],"issn-type":[{"value":"2667-3681","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of clinical relevance of weight nadirs and weight regain during 3 years of treatment with tirzepatide in participants with obesity or overweight and prediabetes","name":"articletitle","label":"Article Title"},{"value":"Obesity Pillars","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.obpill.2026.100333","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Eli Lilly and Company. Published by Elsevier Inc. on behalf of Obesity Medicine Association.","name":"copyright","label":"Copyright"}],"article-number":"100333"}}